VANI Vivani Medical, Inc.
Financings ·
Vivani will sell 1,689,200 shares in a registered direct offering and 1,351,351 shares in a private placement at $1.48 each. ThinkEquity is sole placement agent for the registered part, and the company used $20,786 thousand in operations in 2024 against $19,690 thousand of year-end cash.
Vivani's Share Purchase Agreement with an entity affiliated with a director and another investor is expected to close in stages through July 15, 2026. The company says the proceeds secure its financial position into the second half of 2026.
Vivani sells 7,936,507 shares at $1.26 to two buyers, one of them tied to chairman Gregg Williams. Cash was $8.1 million at June 30, 2025, and the release presents the new money as securing its position into the second half of 2026.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $18.1 million | $15.7 million |
| Net income (loss) | -$26.6 million | -$23.5 million |
| Cash from operations | -$24.3 million | -$20.8 million |
| Cash and equivalents | $16.2 million | $18.4 million |
Our latest story on this, dated Jan 27, 2026: "Vivani Medical prices $4.5 million stock offering; chairman's affiliate to buy $2.0 million". The story links the filing or release it is based on. Read the story.
Vivani Medical, Inc. trades under the ticker VANI on NASDAQ.
Vivani Medical, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:U5P.
The SEC Central Index Key (CIK) for Vivani Medical, Inc. is 1266806. Its filings are on SEC EDGAR.
90,203,356 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Vivani Medical, Inc. under United States.
Our directory classifies Vivani Medical, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Vivani Medical, Inc. is US92854B1098.
aibio.space lists Vivani Medical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Vivani Medical, Inc. reported a net loss of $26.6 million for the fiscal year ended Dec 31, 2025, and used $24.3 million of cash in operations, per its annual report to the SEC.
$18.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$19.9 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Vivani Medical, dated Jan 27, 2026: "Vivani Medical prices $4.5 million stock offering; chairman's affiliate to buy $2.0 million". Vivani will sell 1,689,200 shares in a registered direct offering and 1,351,351 shares in a private placement at $1.48 each. ThinkEquity is sole placement agent for the registered part, and the company used $20,786 thousand in operations in 2024 against $19,690 thousand of year-end cash. Source.
From our story of Jan 27, 2026: The report says the financial statements are prepared on a going-concern basis. Source.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio